However, the combination of WT1-TCB and Ven/Aza resulted in significant anti-tumor activity in terms of reduced tumor growth (978 ± 247 mm3; p = 0.0023) but also prolongation of the median survival (p = 0.0034) compared to the vehicle control on day 36 (Fig. 2F–H). Here, WT1 is linked to neoplasm.